Payment overview · 2025
General Payments
$431.37
21 reported records · 6 companies
Healthcare provider profile · identity verified
Fernando T. Itable, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MILWAUKEE, WI · NPI 1871586560
Verified facts
What the public records show
CMS Open Payments records show Fernando T. Itable, M.D. received $431.37 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 32.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Symbicort by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Biktarvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $140.11 | 32.5% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $103.19 | 23.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $78.67 | 18.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.92 | 14.3% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $24.14 | 5.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.34 | 5.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $431.37 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $78.19 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $68.85 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $63.70 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.92 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.92 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.34 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 74 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
110 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
74 | 14 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
104 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
91 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 371 | 69 |
| Omeprazole | Omeprazole | 272 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 263 | 56 |
| Tramadol Hcl | Tramadol Hcl | 251 | 41 |
| Gabapentin | Gabapentin | 243 | 39 |
| Losartan Potassium | Losartan Potassium | 232 | 43 |
| Amoxicillin | Amoxicillin | 223 | 69 |
| Tizanidine Hcl | Tizanidine Hcl | 218 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 216 | 32 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 189 | 34 |
| Prednisone | Prednisone | 187 | 37 |
| Ibuprofen | Ibuprofen | 174 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 157 | 34 |
| Famotidine | Famotidine | 149 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 144 | 25 |
| Furosemide | Furosemide | 142 | 28 |
| Diazepam | Diazepam | 136 | 20 |
| Amlodipine Besylate | Amlodipine Besylate | 130 | 26 |
| Potassium Chloride | Potassium Chloride | 129 | 25 |
| Metformin Hcl Er | Metformin Hcl | 116 | 21 |
| Linzess | Linaclotide | 110 | 16 |
| Trazodone Hcl | Trazodone Hcl | 106 | 24 |
| Azithromycin | Azithromycin | 105 | 42 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 104 | 18 |
| Trulicity | Dulaglutide | 104 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 100 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 32 |
| Montelukast Sodium | Montelukast Sodium | 97 | 14 |
| Bupropion Xl | Bupropion Hcl | 94 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 94 | 16 |
| Atenolol | Atenolol | 92 | 18 |
| Ozempic | Semaglutide | 91 | 15 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 86 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 85 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 83 | 20 |
| Simvastatin | Simvastatin | 83 | 16 |
| Fluconazole | Fluconazole | 82 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | suppressed |
| Lisinopril | Lisinopril | 80 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 78 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 78 | 14 |
| Jardiance | Empagliflozin | 74 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 74 | 14 |
| Sertraline Hcl | Sertraline Hcl | 73 | 12 |
| Alendronate Sodium | Alendronate Sodium | 71 | suppressed |
| Alprazolam | Alprazolam | 71 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 70 | suppressed |
| Ondansetron Odt | Ondansetron | 66 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | suppressed |
| Levofloxacin | Levofloxacin | 65 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | suppressed |
| Allopurinol | Allopurinol | 60 | 14 |
| Metformin Hcl | Metformin Hcl | 60 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 13 |
| Topiramate | Topiramate | 58 | 11 |
| Valsartan | Valsartan | 57 | 13 |
| Eliquis | Apixaban | 52 | suppressed |
| Carvedilol | Carvedilol | 51 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | 11 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 49 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 49 | 17 |
| Doxepin Hcl | Doxepin Hcl | 48 | suppressed |
| Spironolactone | Spironolactone | 48 | suppressed |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 12 |
| Pregabalin | Pregabalin | 44 | suppressed |
| Mirtazapine | Mirtazapine | 43 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 43 | 13 |
| Promethazine Hcl | Promethazine Hcl | 42 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Lorazepam | Lorazepam | 37 | suppressed |
| Meloxicam | Meloxicam | 36 | suppressed |
| Clonazepam | Clonazepam | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 35 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Lidocaine | Lidocaine | 34 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 32 | 15 |
| Naproxen | Naproxen | 31 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Loperamide | Loperamide Hcl | 28 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 27 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Metronidazole | Metronidazole | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 19 |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Premarin | Estrogens, Conjugated | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Vraylar | Cariprazine Hcl | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 15 | suppressed |
| Meprobamate | Meprobamate | 15 | suppressed |
| Nexium | Esomeprazole Magnesium | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 15 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 15 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Humalog | Insulin Lispro | 14 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Nateglinide | Nateglinide | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Amitiza | Lubiprostone | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 11 | suppressed |
| Restasis Multidose | Cyclosporine | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $431.37 · 21 records | Novo Nordisk Inc | AIRSUPRA, JARDIANCE, Kerendia, MOUNJARO, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error